

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Barlogie-Salmon Myeloma Committee

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Amrita Y. Krishnan, MD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair: Jing Christine Ye, MD, MSc
 Executive Officer: Alex Herrera, MD
 Statisticians: Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation: Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging: Eric M. Rohren, MD, PhD
 Pathology: Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

NCORP Representative: Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
 Daria Chugina, MD, CCRPS
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals: Brandon Richard Labadie, CCRP
 Patient Advocate: Paul Gater, MPhil
 Pharmaceutical Science: Craig Elg, PharmD
 Yumena Kawasaki, PharmD
 Protocol Project Manager: Amy Doyle
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Saturday, October 10, 2026 11:30 a.m. - 1:30 p.m.
 Room: Comiskey (Concourse Level)

Agenda

Welcome & Introductions - Amrita Krishnan, MD, FACP

Keynote Speaker - Ola Landgren, MD, PhD

Active Trials Updates

1. S2213/BMT CTN 2025 - Patrick Hagen, MD
2. S1803/BMT CTN 1706 - Amrita Krishnan, MD, FACP
3. S2005 - Sikander Ailawadhi, MD
4. S2209 - Sikander Ailawadhi, MD

Update on Trials in Development

1. **S2508**, "A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Patients with Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe, J.C. Ye, and A. Cowan.
2. Phase III Non-inferiority RCT of Fixed Duration versus Continuous anti-CD38 in Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma - Hira Mian, MD & Jeries Kort, MD
3. Ramantamig Dara for NDMM - Murali Janakiram, MD & Sikander Ailawadhi, MD
4. A Randomized Phase II Study of Teclistamab + Iberdomide vs. Teclistamab Alone for Relapsed/Refractory Myeloma - Ricardo D. Parrondo, MD

Data use of closed trials/S0777 Manuscript - Sikander Ailawadhi, MD & Antje Hoering, PhD

TM Subcommittee update - J. Christine Ye., MD & Brian Walker, BSc, PhD

- Sample status S1803
- PO1 update

Other Cooperative Group Trials Updates

1. **A062102**, "Randomized Phase II Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients." Dr. R. Banerjee. Activated: 4/4/24; Temporarily closed to accrual: 6/3/26.
2. **EEA173**, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Dr. M. Butler. Activated: 4/30/19.
3. **EEA181**, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Dr. K. Gowin. Activated: 10/27/20.
4. **EEA242**, "Randomized Phase Ib/II Study of Teclistamab + Pomalidomide (TP) vs. Carfilzomib + Pomalidomide + Dexamethasone (KPD) in Multiple Myeloma with Early Relapse"
5. **A062401**, "Quadruplet induction followed by teclistamab consolidation and doublet maintenance in patients with primary plasma cell leukemia: The QUANTUM Trial." Dr. Goldsmith

Barlogie-Salmon Myeloma Committee

Active Studies

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/8/22; Re-activated: 3/1/26.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Li-pe, T. Chauncey, and K. Gowin. Activated 5/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/1/23

Closed Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19. Registration Step 1 Closed to Accrual: 1/15/25.

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16; Completed: 4/17/26.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchorawala. Activated: 3/8/18; Closed: 9/30/19; Completed: 10/21/25.

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Re-lapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15; Complete: 1/17/25.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmacyproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

BMTCTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13; Completed: 11/15/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodapkar. Activated: 1/17/11. Closed: 7/14/17.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed 3/3/23; Completed: 1/31/25.

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S0777 Interim Analysis in Clinical Trials: Caution Against Premature Conclusions – The SWOG Multiple Myeloma S0777 Case Study. Goren E, Sexton R, Orlovski R, Hoering A. *Trials*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42661196/>

Submitted Manuscripts

None this cycle.

Myeloma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>A062102</i>	<i>EAA173</i>	<i>EAA181</i>
AdventHealth Parker	2	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	3	-	-	-	-
Boston Medical Center	5	-	-	3	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	28	-	-	-	-	8	-
Cancer Research for the Ozarks NCORP	2	-	2	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	5	-	1	1	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	2	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	23	2	-	-	-	-	-
Cedars-Sinai Medical Center	6	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	118	-	6	-	-	-	-
Columbia University NCI Community Oncology Research Program	-	-	1	4	-	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	4	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	1	-	-	1	-
Fred Hutchinson Cancer Research Center LAPS	7	-	-	-	1	9	-
Froedtert and the Medical College of Wisconsin LAPS	12	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	21	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	4	-	-	-	-	-	-
Heartland Cancer Research NCORP	12	-	5	-	-	-	-
Henry Ford Hospital	2	1	-	-	-	4	2
Houston Methodist Hospital	13	-	-	2	-	-	-
Intermountain Medical Center	-	1	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	60	-	12	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	4	-	-	-	-
Lahey Clinic	3	-	-	-	-	-	-
Loyola University Medical Center	26	-	-	1	-	3	4
MU Health Care Goldschmidt Cancer Center	3	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	1	-	-	-	2
Medical University of South Carolina NCORP Community Site	60	-	-	-	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	13	-	2	-	-	-	-
Moffitt Cancer Center	48	-	-	-	-	-	-

Myeloma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>A062102</i>	<i>EAA173</i>	<i>EAA181</i>
Montana Cancer Consortium NCORP	1	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	5	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	1	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-	-	-	-
Oregon Health and Science University	33	-	1	-	-	3	9
Our Lady of the Lake Hospital	-	-	-	-	-	1	-
Pacific Cancer Research Consortium NCORP	18	-	7	1	-	-	-
Regents of the University of Michigan	16	-	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	4	-	-	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	15	-	5	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	35	-	-	1	-	-	-
Tulane University School of Medicine	-	-	-	-	-	2	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	19	-	-	-	-	-	-
University of Arizona LAPS	12	-	-	-	-	-	5
University of Arkansas for Medical Sciences	-	-	8	-	-	-	5
University of California Davis Comprehensive Cancer Center	27	-	7	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	2
University of Kentucky/Markey Cancer Center	4	-	-	-	-	3	-
University of Nebraska Medical Center	-	-	-	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	5	-	-	-	-
University of Rochester LAPS	15	2	4	-	-	-	8
University of Texas MD Anderson Cancer Center LAPS	27	-	4	2	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	-	-	-	4	2
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	1	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	18	-	3	1	-	-	-
Wisconsin NCI Community Oncology Research Program	23	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5	2	-	4	8
ALLIANCE	226	4	16	12	-	-	-
CCTG	21	-	-	-	-	-	-
ECOG-ACRIN	188	22	14	9	-	-	-
NRG	117	1	5	2	-	-	-
Total	1,338	34	136	46	1	44	48

